What will be RAPT Therapeutics stock price at the end of Q1 2025?
Below $1.00 • 25%
$1.00 to $1.50 • 25%
$1.51 to $2.00 • 25%
Above $2.00 • 25%
Publicly available stock price data from financial news outlets or stock exchange listings
RAPT Therapeutics Announces $150 Million Private Placement at $0.85/Share, 90.4% Pre-Market Surge, and License Agreement with Shanghai Jemincare
Dec 23, 2024, 01:31 PM
RAPT Therapeutics has announced a $150 million private placement, which includes 176.5 million shares and warrants priced at $0.85 per share. The company also entered an exclusive license agreement with Shanghai Jemincare for its novel long-acting anti-IgE antibody, JYB1904 (RPT904). Under this agreement, RAPT will retain worldwide rights to the drug, excluding mainland China, Hong Kong, Macau, and Taiwan. Jemincare will receive a $35 million upfront payment and could earn up to $672.5 million in milestone payments. Following these announcements, RAPT's stock experienced a significant pre-market increase of 90.4% and was up 74% during trading hours.
View original story
Remains 20% or more below pre-announcement level • 25%
Recovers to within 10% of pre-announcement level • 25%
Other • 25%
Exceeds pre-announcement level • 25%
Above $30 • 25%
Below $10 • 25%
$10-$20 • 25%
$20-$30 • 25%
Decrease • 25%
Increase by less than 10% • 25%
Increase by 10% or more • 25%
No change • 25%
Below $200 • 25%
Above $300 • 25%
$250 to $300 • 25%
$200 to $250 • 25%
$45-$50 • 25%
Above $50 • 25%
Below $40 • 25%
$40-$45 • 25%
Above $700 • 25%
$600 to $700 • 25%
$500 to $600 • 25%
Below $500 • 25%
Increase by more than 10% • 25%
Decrease by more than 10% • 25%
Decrease by 0-10% • 25%
Increase by 0-10% • 25%
Below $2 • 25%
Above $4 • 25%
$3 to $4 • 25%
Above $1.00 • 25%
$0.75 to $1.00 • 25%
$0.50 to $0.75 • 25%
$2 to $3 • 25%
Below $0.50 • 25%
$275-$300 • 25%
Above $300 • 25%
$250-$275 • 25%
Below $250 • 25%
Below $2.00 • 25%
Above $3.00 • 25%
$2.51 - $3.00 • 25%
$2.00 - $2.50 • 25%
Below $5 • 25%
Above $15 • 25%
$10 to $15 • 25%
$5 to $10 • 25%
Yes • 50%
No • 50%
Phase 2 trial completion • 25%
No significant milestone • 25%
Regulatory approval in any region • 25%
Phase 3 trial initiation • 25%